OBJECTIVE: To systematically evaluate the efficacy and safety of sacubitril valsartan in the treatment of hypertension

so as to provide evidence-based medical evidence for clinical practice. METHODS: PubMed

Embase

the Cochrane Library

CNKI

Wanfang Data and VIP were retrieved to collect the randomized controlled trials（RCT） of sacubitril valsartan in the treatment of hypertension. The retrieval time was from the establishment of the data base to Nov. 30 th

2021. Two investigators independently performed literature screening

data extraction and bias risk assessment. Review Manager 5.4 was used for data synthesis. RESULTS: A total of 14 RCT（15 articles） were enrolled

including 11 428 patients with hypertension. The control drug was angiotensin Ⅱ receptor blocker in 13 studies and amlodipine in 1 study; most studies used the daily dose of sacubitril valsartan for 400 mg; and 9 studies had a follow-up of ≤8 weeks. Compared with the control group（valsartan

olmersartan and amlodipine）

sacubitril valsartan significantly reduced mean sitting systolic

diastolic blood pressure

mean ambulatory systolic and diastolic blood pressure

and significantly increased the rate of blood pressure control without increasing the risk of adverse events. CONCLUSIONS: Sacubitril valsartan may be more effective than conventional therapy in reducing blood pressure in patients with hypertensive without significantly increasing the incidence of adverse events. More clinical studies are still needed in the future to investigate the effects of age

gender

race and different population characteristics on the antihypertensive effect of sakubatril valsartan and to observe its long-term adverse effects.